Zelluna ASA
7UM
Company Profile
Business description
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.
Contact
Ullernchausseen 64
Oslo0379
NORT: +47 41380080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,157.90 | 0.80 | -0.01% |
| CAC 40 | 8,087.12 | 44.17 | 0.55% |
| DAX 40 | 23,044.60 | 152.92 | 0.67% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,689.16 | 42.37 | 0.49% |
| HKSE | 23,905.56 | 215.84 | 0.91% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,608.49 | 68.57 | -0.18% |
| NZX 50 Index | 12,128.21 | 14.67 | 0.12% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,936.90 | 5.70 | 0.07% |
| SSE Composite Index | 3,370.03 | 5.20 | 0.15% |